About Adamas Pharmaceuticals (NASDAQ:ADMS)
Adamas Pharmaceuticals, Inc. discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease. The company's product candidates under development includes ADS-5102, which is in Phase III clinical trials for the treatment of multiple sclerosis walking impairment; and in Phase II clinical trials for additional indications, such as the treatment of wearing OFF and delaying motor complications in Parkinson's disease, tardive dyskinesia, Huntington's chorea, and Tourette syndrome, as well as non-motor disorders consisting of depression, and anti-psychotic induced weight gain. Its products under development also includes ADS-4101, a modified-release lacosamide that has completed Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMS
CUSIPN/A
Phone510-450-3500
Debt
Debt-to-Equity Ratio1.55%
Current Ratio10.79%
Quick Ratio10.69%
Price-To-Earnings
Trailing P/E Ratio-7.08
Forward P/E Ratio-4.79
P/E GrowthN/A
Sales & Book Value
Annual Sales$570,000.00
Price / Sales1,321.22
Cash FlowN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book9.69
Profitability
EPS (Most Recent Fiscal Year)($3.97)
Net Income$-89,490,000.00
Net MarginsN/A
Return on Equity-95.30%
Return on Assets-59.49%
Miscellaneous
Employees147
Outstanding Shares26,810,000
Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions
What is Adamas Pharmaceuticals' stock symbol?
Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."
How were Adamas Pharmaceuticals' earnings last quarter?
Adamas Pharmaceuticals (NASDAQ:ADMS) posted its quarterly earnings results on Thursday, February, 22nd. The specialty pharmaceutical company reported ($1.27) EPS for the quarter, missing the Zacks' consensus estimate of ($1.18) by $0.09. The specialty pharmaceutical company had revenue of $0.57 million for the quarter, compared to analysts' expectations of $0.84 million. The firm's revenue was up 1435.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.68) EPS. View Adamas Pharmaceuticals' Earnings History.
What price target have analysts set for ADMS?
11 brokers have issued 1-year price objectives for Adamas Pharmaceuticals' shares. Their forecasts range from $31.00 to $55.00. On average, they expect Adamas Pharmaceuticals' stock price to reach $43.3750 in the next twelve months. View Analyst Ratings for Adamas Pharmaceuticals.
What are Wall Street analysts saying about Adamas Pharmaceuticals stock?
Here are some recent quotes from research analysts about Adamas Pharmaceuticals stock:
- 1. Mizuho analysts commented, "We believe Adamas is building a solid case for the importance of Gocovri within the Parkinson’s treatment paradigm, thereby increasing the company’s attractiveness as a takeout candidate longer-term. We reiterate our Buy rating and $49 PT." (4/20/2018)
- 2. According to Zacks Investment Research, "Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. " (2/23/2018)
Who are some of Adamas Pharmaceuticals' key competitors?
Some companies that are related to Adamas Pharmaceuticals include Radius Health (RDUS), Impax Laboratories (IPXL), Pacira Pharmaceuticals (PCRX), Zogenix (ZGNX), Prothena (PRTA), ImmunoGen (IMGN), Immuron (IMRN), Myovant Sciences (MYOV), G1 Therapeutics (GTHX), TherapeuticsMD (TXMD), Apellis Pharmaceuticals (APLS), Endo International (ENDP), WAVE Life Sciences (WVE), Theravance Biopharma (TBPH), PTC Therapeutics (PTCT), Mallinckrodt (MNK), Revance Therapeutics (RVNC) and Dynavax Technologies (DVAX).
Who are Adamas Pharmaceuticals' key executives?
Adamas Pharmaceuticals' management team includes the folowing people:
- Dr. Gregory T. Went Ph.D., Co-Founder, Chairman & CEO (Age 54)
- Ms. Jennifer J. Rhodes, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 48)
- Dr. Rajiv Patni M.D., Chief Medical Officer (Age 49)
- Mr. Alfred G. Merriweather, Chief Financial Officer (Age 64)
- Mr. Richard A. King, Chief Operating Officer (Age 53)
Has Adamas Pharmaceuticals been receiving favorable news coverage?
News headlines about ADMS stock have trended somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Adamas Pharmaceuticals earned a news sentiment score of 0.10 on Accern's scale. They also assigned headlines about the specialty pharmaceutical company an impact score of 45.81 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Adamas Pharmaceuticals' major shareholders?
Adamas Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include STATE STREET CORP (10.46%). Company insiders that own Adamas Pharmaceuticals stock include Christopher B Prentiss, Great Point Partners Llc, Gregory T Went, Ix Lp Mdv, Jennifer J Rhodes, Rajiv Patni, William J Dawson and William W Ericson. View Institutional Ownership Trends for Adamas Pharmaceuticals.
How do I buy shares of Adamas Pharmaceuticals?
Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adamas Pharmaceuticals' stock price today?
One share of ADMS stock can currently be purchased for approximately $28.09.
How big of a company is Adamas Pharmaceuticals?
Adamas Pharmaceuticals has a market capitalization of $753.01 million and generates $570,000.00 in revenue each year. The specialty pharmaceutical company earns $-89,490,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. Adamas Pharmaceuticals employs 147 workers across the globe.
How can I contact Adamas Pharmaceuticals?
Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 750, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]
MarketBeat Community Rating for Adamas Pharmaceuticals (ADMS)
MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Adamas Pharmaceuticals (NASDAQ:ADMS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Adamas Pharmaceuticals in the last 12 months. Their average twelve-month price target is $43.3750, suggesting that the stock has a possible upside of 54.41%. The high price target for ADMS is $55.00 and the low price target for ADMS is $31.00. There are currently 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $43.3750 | $46.00 | $45.6667 | $39.50 |
| Price Target Upside: | 54.41% upside | 76.79% upside | 7.07% upside | 78.41% upside |
Adamas Pharmaceuticals (NASDAQ:ADMS) Consensus Price Target History
Adamas Pharmaceuticals (NASDAQ:ADMS) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Adamas Pharmaceuticals (NASDAQ:ADMS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Adamas Pharmaceuticals (NASDAQ ADMS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 29.00%
Institutional Ownership Percentage: 77.33%
Adamas Pharmaceuticals (NASDAQ ADMS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/21/2018 | Christopher B Prentiss | CAO | Sell | 567 | $25.98 | $14,730.66 | 17,758 |  |
| 3/21/2018 | Gregory T Went | CEO | Sell | 4,541 | $25.75 | $116,930.75 | 182,610 | |
| 3/21/2018 | Rajiv Patni | Insider | Sell | 1,252 | $25.94 | $32,476.88 | 21,515 | |
| 12/21/2017 | Jennifer J. Rhodes | Insider | Sell | 440 | $32.30 | $14,212.00 | | |
| 6/21/2017 | Great Point Partners Llc | Major Shareholder | Sell | 380,000 | $17.08 | $6,490,400.00 | | |
| 6/21/2017 | Jennifer J. Rhodes | Insider | Sell | 1,041 | $17.53 | $18,248.73 | | |
| 6/19/2017 | Great Point Partners Llc | Major Shareholder | Sell | 350,000 | $17.05 | $5,967,500.00 | | |
| 3/21/2017 | Gregory T Went | CEO | Sell | 2,807 | $17.03 | $47,803.21 | 166,526 | |
| 3/21/2017 | Rajiv Patni | Insider | Sell | 733 | $17.04 | $12,490.32 | 13,642 | |
| 3/21/2017 | William J Dawson | CFO | Sell | 716 | $17.02 | $12,186.32 | 14,284 | |
| 9/16/2016 | Ix Lp Mdv | Major Shareholder | Buy | 62,977 | $16.48 | $1,037,860.96 | | |
| 9/13/2016 | Ix Lp Mdv | Major Shareholder | Buy | 84,376 | $15.58 | $1,314,578.08 | | |
| 9/7/2016 | William W Ericson | Director | Buy | 60,846 | $15.68 | $954,065.28 | | |
| 9/6/2016 | Ix Lp Mdv | Major Shareholder | Buy | 50,919 | $14.79 | $753,092.01 | | |
| 9/6/2016 | William W Ericson | Director | Buy | 7,200 | $15.00 | $108,000.00 | | |
| 9/2/2016 | William W Ericson | Director | Buy | 43,719 | $14.75 | $644,855.25 | | |
| 4/18/2016 | Natalie Mcclure | SVP | Sell | 36,000 | $18.50 | $666,000.00 | 21,006 | |
| 12/7/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $16.23 | $48,690.00 | 48,000 | |
| 10/5/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $16.75 | $50,250.00 | 54,000 | |
| 9/8/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $19.13 | $57,390.00 | 57,000 | |
| 7/6/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $25.91 | $77,730.00 | | |
| 6/5/2015 | Natalie Mcclure | SVP | Sell | 2,000 | $18.95 | $37,900.00 | | |
| 5/18/2015 | Ix Lp Mdv | Major Shareholder | Sell | 1,643 | $18.04 | $29,639.72 | | |
| 5/15/2015 | Richard H Booth | Director | Sell | 1,000 | $17.85 | $17,850.00 | | |
| 5/14/2015 | Gregory T Went | CEO | Sell | 2,728 | $18.00 | $49,104.00 | | |
| 4/23/2015 | Gregory T Went | CEO | Sell | 3,300 | $18.00 | $59,400.00 | | |
| 4/21/2015 | Gregory T Went | CEO | Sell | 962 | $18.01 | $17,325.62 | | |
| 4/20/2015 | Gregory T Went | CEO | Sell | 2,610 | $18.00 | $46,980.00 | | |
| 4/15/2015 | Richard H Booth | Director | Sell | 1,000 | $17.72 | $17,720.00 | | |
| 4/14/2015 | Gregory T Went | CEO | Sell | 14,757 | $7.15 | $105,512.55 | | |
| 4/10/2015 | William W Ericson | Director | Sell | 37,078 | $18.56 | $688,167.68 | | |
| 4/6/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $17.44 | $52,320.00 | | |
| 4/6/2015 | Natalie Mcclure | SVP | Sell | 2,000 | $17.44 | $34,880.00 | | |
| 3/19/2015 | Gregory T Went | CEO | Sell | 23,088 | $18.00 | $415,584.00 | | |
| 3/18/2015 | Ix Lp Mdv | Major Shareholder | Sell | 11,723 | $18.02 | $211,248.46 | | |
| 3/16/2015 | Richard H Booth | Director | Sell | 1,000 | $17.36 | $17,360.00 | | |
| 3/13/2015 | Aeris Capital Equity Investmen | Major Shareholder | Sell | 350,000 | $17.23 | $6,030,500.00 | | |
| 2/17/2015 | Richard H Booth | Director | Sell | 1,000 | $16.54 | $16,540.00 | | |
| 2/5/2015 | Natalie Mcclure | SVP | Sell | 2,000 | $16.87 | $33,740.00 | | |
| 2/2/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $16.77 | $50,310.00 | | |
| 1/5/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $17.59 | $52,770.00 | | |
| 1/5/2015 | Natalie Mcclure | SVP | Sell | 2,000 | $17.59 | $35,180.00 | | |
| 12/24/2014 | Richard H Booth | Director | Sell | 2,000 | $17.51 | $35,020.00 | | |
| 12/3/2014 | Aeris Capital Equity Investmen | Major Shareholder | Sell | 111,625 | $14.51 | $1,619,678.75 | | |
| 12/1/2014 | Aeris Capital Equity Investmen | Major Shareholder | Sell | 13,615 | $14.54 | $197,962.10 | | |
| 12/1/2014 | Natalie Mcclure | SVP | Sell | 20,000 | $14.50 | $290,000.00 | | |
| 11/26/2014 | Aeris Capital Equity Investmen | Major Shareholder | Sell | 12,500 | $14.77 | $184,625.00 | | |
| 11/25/2014 | Aeris Capital Equity Investmen | Major Shareholder | Sell | 10,000 | $14.85 | $148,500.00 | | |
| 4/15/2014 | William W Ericson | Director | Buy | 300,000 | $16.00 | $4,800,000.00 | | |
(Data available from 1/1/2013 forward)
Adamas Pharmaceuticals (NASDAQ ADMS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Adamas Pharma (ADMS) Reports Final Results from Two-Year Phase 3 Open-Label Study of GOCOVRI
www.streetinsider.com - April 21 at 9:01 AM |
 | Adamas Pharmaceuticals (ADMS) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - April 21 at 7:06 AM |
| Mizuho Reiterates "Buy" Rating for Adamas Pharmaceuticals (ADMS)
www.americanbankingnews.com - April 20 at 7:46 AM |
 | Adamas Pharmaceuticals Inc’s (NASDAQ:ADMS) Earnings Dropped -49.01%, How Did It Fare Against The Industry?
finance.yahoo.com - April 19 at 4:49 PM |
| Adamas Pharmaceuticals (ADMS) Expected to Announce Quarterly Sales of $1.68 Million
www.americanbankingnews.com - April 19 at 3:06 AM |
| Q1 2018 EPS Estimates for Adamas Pharmaceuticals Decreased by Analyst (ADMS)
www.americanbankingnews.com - April 18 at 7:58 AM |
 | JF's Core Biotech Buys #11: Positive News For Several Holdings, A Change To Benchmarks And Introducing Our 17th ...
seekingalpha.com - April 17 at 4:46 PM |
| Brokerages Anticipate Adamas Pharmaceuticals (ADMS) Will Announce Earnings of -$1.38 Per Share
www.americanbankingnews.com - April 17 at 1:19 PM |
| Adamas Pharmaceuticals (ADMS) PT Set at $45.00 by Cowen
www.americanbankingnews.com - April 11 at 7:53 PM |
| Adamas Pharmaceuticals (ADMS) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - April 9 at 10:19 PM |
| 3 Things In Biotech, April 5: Pfizer's Game Changer, Adamas Tackles MS, Aeglea Dives Into Small Cell
seekingalpha.com - April 6 at 9:29 AM |
| Adamas Pharmaceuticals (ADMS) to Post Q1 2018 Earnings of ($1.41) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - April 6 at 6:48 AM |
| Adamas Pharma (ADMS) Reports 1st Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment
www.streetinsider.com - April 5 at 9:31 AM |
| Adamas Pharmaceuticals (ADMS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 5:34 PM |
| Adamas Pharmaceuticals (ADMS) Now Covered by Leerink Swann
www.americanbankingnews.com - April 4 at 9:30 AM |
| Adamas Pharmaceuticals (ADMS) Upgraded at ValuEngine
www.americanbankingnews.com - April 3 at 8:10 PM |
| Adamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment
finance.yahoo.com - April 3 at 9:25 AM |
| $1.37 Million in Sales Expected for Adamas Pharmaceuticals Inc (ADMS) This Quarter
www.americanbankingnews.com - April 2 at 3:06 AM |
| Adamas Pharmaceuticals (ADMS) Price Target Raised to $48.00
www.americanbankingnews.com - April 1 at 9:41 AM |
| Zacks: Brokerages Anticipate Adamas Pharmaceuticals Inc (ADMS) Will Post Earnings of -$1.37 Per Share
www.americanbankingnews.com - March 31 at 1:20 PM |
| Adamas Pharmaceuticals (ADMS) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 30 at 9:28 PM |
| Adamas Pharmaceuticals (ADMS) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - March 27 at 5:10 PM |
| Gocovri Stabilizes Adamas Stock, Secures Another Buy Rating
finance.yahoo.com - March 27 at 4:47 PM |
| Adamas Pharmaceuticals (ADMS) Earns Buy Rating from Analysts at Bank of America
www.americanbankingnews.com - March 27 at 10:07 AM |
| Adamas: Valuation Report
seekingalpha.com - March 27 at 9:10 AM |
| Christopher B. Prentiss Sells 567 Shares of Adamas Pharmaceuticals Inc (ADMS) Stock
www.americanbankingnews.com - March 22 at 8:13 PM |
| Adamas Pharmaceuticals Inc (ADMS) Insider Sells $32,476.88 in Stock
www.americanbankingnews.com - March 22 at 8:13 PM |
| Gregory T. Went Sells 4,541 Shares of Adamas Pharmaceuticals Inc (ADMS) Stock
www.americanbankingnews.com - March 22 at 7:32 PM |
| Adamas Pharmaceuticals (ADMS) versus CymaBay Therapeutics (CBAY) Financial Analysis
www.americanbankingnews.com - March 20 at 7:10 PM |
| Edited Transcript of ADMS earnings conference call or presentation 22-Feb-18 9:30pm GMT
finance.yahoo.com - March 20 at 4:49 PM |
| Adamas Pharma (ADMS) Announces Publication of Data Supporting Benefits of GOCOVRI in PD Patients with ... - StreetInsider.com
www.streetinsider.com - March 16 at 10:03 AM |
| Adamas Announces Publication of Data Supporting the Benefits of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
finance.yahoo.com - March 15 at 10:18 AM |
| Adamas Pharmaceuticals Inc (ADMS) Expected to Post Earnings of -$1.32 Per Share
www.americanbankingnews.com - March 14 at 12:01 PM |
 | Adamas stock rises 5% on strong launch of Parkinson's drug - MarketWatch
www.marketwatch.com - March 13 at 5:00 PM |
 | BRIEF-Adamas Pharmaceuticals Says As Of Feb 28, Co Received Prescriptions For Gocovri From About 390 Distinct Prescribers
www.reuters.com - March 13 at 10:50 AM |
| Pre-Open Movers 03/12: (OCLR) (ADMS) (MU) Higher; (ANTH) (SVRA) (ESPR) Lower (more...)
www.streetinsider.com - March 12 at 4:44 PM |
| What Should Investors Know About Adamas Pharmaceuticals Inc’s (NASDAQ:ADMS) Future?
finance.yahoo.com - March 12 at 4:44 PM |
| Adamas stock rises 5% on strong launch of Parkinson's drug
finance.yahoo.com - March 12 at 4:44 PM |
| Adamas Pharmaceuticals Inc (ADMS) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 10 at 6:12 PM |
| Adamas Pharmaceuticals (ADMS) Upgraded to Hold by BidaskClub
www.americanbankingnews.com - March 10 at 9:45 AM |
| Tamarack Advisers LP Takes Position in Adamas Pharmaceuticals Inc (ADMS)
www.americanbankingnews.com - March 6 at 10:30 AM |
| Mosaic Family Wealth LLC Sells 26,000 Shares of Adamas Pharmaceuticals Inc (ADMS)
www.americanbankingnews.com - March 6 at 8:48 AM |
| Adamas Pharmaceuticals (ADMS) Cut to Sell at BidaskClub
www.americanbankingnews.com - March 4 at 12:16 AM |
| EAM Investors LLC Buys 4,792 Shares of Adamas Pharmaceuticals Inc (ADMS)
www.americanbankingnews.com - February 28 at 1:56 PM |
| American Century Companies Inc. Acquires New Stake in Adamas Pharmaceuticals Inc (ADMS)
www.americanbankingnews.com - February 27 at 4:06 AM |
| Adamas Pharmaceuticals (ADMS) PT Set at $40.00 by Needham & Company LLC
www.americanbankingnews.com - February 26 at 11:26 AM |
| Adamas Pharmaceuticals (ADMS) Rating Reiterated by Noble Financial
www.americanbankingnews.com - February 24 at 11:58 AM |
| Adamas Pharmaceuticals (ADMS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - February 23 at 5:51 PM |
| Here's Why Adamas Pharmaceuticals Dropped Today
finance.yahoo.com - February 23 at 4:43 PM |
| Research Analysts Set Expectations for Adamas Pharmaceuticals Inc's FY2018 Earnings (ADMS)
www.americanbankingnews.com - February 23 at 1:22 PM |
Adamas Pharmaceuticals (NASDAQ:ADMS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Adamas Pharmaceuticals (NASDAQ:ADMS) Income Statement, Balance Sheet and Cash Flow Statement
Adamas Pharmaceuticals (NASDAQ ADMS) Stock Chart for Monday, April, 23, 2018
Loading chart…
